Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
The centre has an initial capacity of 500 FTEs
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
